|
T4052 |
KML29
|
|
Lipase
|
|
KML29 is highly selective and effective monoacylglycerol lipase (MAGL) inhibitor. It has effective inhibition of human/mouse/rat MAGL (IC50: 5.9/15/43 nM). It has not inhibitory for FAAH (IC50 > 50 μM). It also effective... |
|
T7831 |
Nitecapone
|
|
Others
,
Transferase
|
|
Nitecapone is a reversible inhibitor of S-COMT (IC50 values of 300 nM in rat liver) |
|
T8505 |
SC-236
|
Sc 236 |
Apoptosis
,
COX
,
PPAR
|
|
SC-236 (Sc 236) is an orally active and selective inhibitor of COX-2 (IC50 of 0.005 μM and 17.8 μM for COX-2 and COX-1, respectively). |
|
T16164 |
MY-5445
|
N-(3-chlorophenyl)-4-phenylphthalazin-1-amine |
PDE
|
|
MY-5445 (N-(3-chlorophenyl)-4-phenylphthalazin-1-amine) is a specific inhibitor of phosphodiesterase type 5 (PDE5). MY-5445 selectively inhibits cGMP PDE (Ki:1.3 μM). |
|
T4691 |
Asimadoline hydrochloride
|
EMD-61753 hydrochloride |
Opioid Receptor
|
|
Asimadoline hydrochloride (EMD-61753 hydrochloride) is a κ-opioid receptor agonist potentially for the treatment of pruritus. Asimadoline hydrochloride has also been shown to be used in the treatment of irritable bowel s... |
|
T4633 |
Asimadoline
|
EMD-61753 |
Opioid Receptor
|
|
Asimadoline (EMD-61753) is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis. Asimadoline... |
|
T10381 |
AS2717638
|
|
Others
|
|
AS2717638 is an orally active and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC50: 38 nM for hLPA5). It also significantly improves PGF2α-, PGE2-, and AMPA-induced allodynia. |
|
TP2068L |
Cyclotraxin B acetate(1203586-72-4 free base)
|
|
Trk receptor
|
|
Cyclotraxin B acetate is an antagonist of TrkB receptors; inhibits BDNF-induced TrkB activity (IC50 = 0.30 nM). Allosterically alters TrkB receptor conformation but does not alter BDNF binding. Prevents BDNF-induced cold... |
|
TP1904L |
FSLLRY-NH2 TFA(245329-02-6 free base)
|
|
Protease-activated Receptor
|
|
FSLLRY-NH2 TFA is a is a protease-activated receptor 2 (PAR2) inhibitor. Reverses taxol-induced mechanical allodynia, heat hyperalgesia and PKC activation in ICR mice. Blocks ERK activation and collagen production in iso... |
|
TP2277 |
Nocistatin(human)
|
Nocistatin (human) |
Others
|
|
Blocker of nociceptin-induced allodynia and hyperalgesia |
|
TP2276 |
Nocistatin (bovine)
|
|
Others
|
|
endogenous peptide used to block nociceptin-induced allodynia and hyperalgesia |
|
T10209 |
A-887826
|
|
Others
|
|
|
|
TP1904 |
FSLLRY-NH2
|
|
|
|
Selective PAR2 peptide antagonist. Reverses taxol-induced mechanical allodynia, heat hyperalgesia and PKC activation in ICR mice. Blocks ERK activation and collagen production in isolated cardiac fibroblasts. Also reduce... |
|
TP2068 |
Cyclotraxin B
|
|
|
|
Antagonist of TrkB receptors; inhibits BDNF-induced TrkB activity (IC50 = 0.30 nM). Allosterically alters TrkB receptor conformation but does not alter BDNF binding. Prevents BDNF-induced cold allodynia in mice. Also sho... |
|
T27752 |
KT109
|
KT-109,KT 109 |
|
|
KT109 is a selective inhibitor of DAGLβ (IC50 = 42 nM). KT109-treated wild-type mice displayed reductions in LPS-induced allodyni as well as in DAGL-β (-/-) micea. Repeated KT109 administration prevented the expression o... |
|
T27025 |
Cizolirtine citrate
|
E-4018,E4018,E 4018 |
|
|
Cizolirtine is a calcitonin gene-related peptide antagonist. Cizolirtine may be useful for alleviating some neuropathic somatosensory disorders, in particular cold allodynia, with a reduced risk of undesirable side effec... |
|
T61091 |
P38-α MAPK-IN-4
|
|
|
|
p38-α MAPK-IN-4 (Compound 69) is a selective inhibitor of p38α MAPK, demonstrating potent inhibition with an IC50 of 1.5 μM. It effectively and swiftly mitigates the onset of mechanical allodynia (MA) in vivo [1]. |
|
T41145 |
TASP 0277308
|
|
|
|
TASP 0277308 is a potent and selective sphingosine 1-phosphate 1 (S1P1) receptor antagonist (IC50 = 7.8 nM). TASP 0277308 inhibits S1P-induced chemotaxis (IC50 = 1.1-1.6 nM), HUVEC cell proliferation (IC50 = 3-3.6 nM) an... |
|
T81658 |
Nocistatin(human) TFA
|
|
|
|
Nocistatin (human) TFA inhibits the allodynia and hyperalgesia induced by nociceptin and mitigates pain triggered by prostaglandin E2 [1]. |
|
T11700 |
J-2156
|
|
Others
|
|
The ED50 of J-2156 in rats for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws was 3.7 and 8.0 mg/kg, respectively. J-2156 is a high potent, selective somatostatin receptor type... |
|
T71206 |
Tiagabine-d6 hydrochloride
|
|
|
|
Tiagabine-d6 is intended for use as an internal standard for the quantification of tiagabine by GC- or LC-MS. Tiagabine is an inhibitor of GABA transporter 1. It inhibits seizures induced by DMCM in mice. Tiagabine reduc... |
|
T71955 |
C3001a
|
|
|
|
C3001a is a selective activator for TREK, against other two-pore domain K+(K2P) channels. C3001a binds to the cryptic binding site formed by P1 and TM4 in TREK-1. C3001a targets TREK channels in the peripheral nervous sy... |
|
T76420 |
Nocistatin
|
|
|
|
Nocistatin, an endogenous neuropeptide, serves as a ligand for the orphan opioid receptor-like receptor and functionally antagonizes the neuropeptide nociceptin/orphanin FQ (Noc/OFQ). It inhibits 5-HT release through a G... |
